Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Proteomics International Laboratories Ltd is a medical technology and biotechnology company specializing in precision diagnostics and bio-analytical services. Its primary focus is the large-scale study of proteins, a field known as proteomics, which is essential for understanding disease mechanisms, diagnostics, and treatment effectiveness. The company is recognized for developing advanced diagnostic tools, such as predictive tests for diabetic kidney disease (PromarkerD) and endometriosis (PromarkerEndo), leveraging proprietary biomarker discovery platforms. By offering both analytical testing services and pipeline products, Proteomics International Laboratories plays a significant role in advancing personalized medicine within the healthcare sector. The company’s certifications, including ISO 15189, underscore its commitment to quality and clinical compliance, which supports the global commercialization of its diagnostic tests. Headquartered in Perth, Australia, it collaborates internationally with research institutions and pharmaceutical companies to expand the reach of its products, aiming to improve disease detection and management across multiple therapeutic areas. Its work positions it as a pioneering contributor to the biotechnology landscape, particularly in the context of early disease detection and the advancement of precision healthcare solutions.